|
|
Volumn 9, Issue 5, 2010, Pages 345-348
|
|
Adaptive trials receive boost
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE;
4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE;
AMG 386;
AMG 655;
ANTINEOPLASTIC AGENT;
CONATUMUMAB;
FIGITUMUMAB;
GLUCAGON LIKE PEPTIDE;
LY 2189265;
TUMOR MARKER;
UNCLASSIFIED DRUG;
BREAST CANCER;
CANCER RESEARCH;
CLINICAL STUDY;
CLINICAL TRIAL;
DOSE CALCULATION;
DRUG EFFICACY;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METHODOLOGY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
SHORT SURVEY;
TREATMENT DURATION;
UNITED STATES;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
DRUG INDUSTRY;
DRUGS, INVESTIGATIONAL;
FEMALE;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 77951880038
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3174 Document Type: Short Survey |
|
Times cited : (14)
|
|
References (0)
|
